James Audia, Ph.D. has served as a member of our board of directors since April 2018. Dr. Audia is the chairman of our scientific advisory board. Dr. Audia is the president and sole proprietor of Audia Consulting, LLC, a scientific consulting firm which he founded in September 2019. Since November 2019, Dr. Audia has served as an entrepreneur in residence for Third Rock Ventures, a venture capital firm, and as the head of medicinal chemistry and senior advisor for Karuna Therapeutics, Inc. Dr. Audia has been an advisor to the Alzheimer’s Association since January 2020. Dr. Audia served as executive director of the Chicago Biomedical Consortium, or CBC, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation, from August 2017 to October 2019 and retains a visiting scholar appointment at Northwestern University. Prior to joining the CBC, Dr. Audia served as the chief scientific officer of Constellation Pharmaceuticals, Inc. from January 2011 to July 2017. Dr. Audia served in various roles at Eli Lilly & Company from 1987 until December 2010. Dr. Audia serves on the board of directors of Constellation Pharmaceuticals, Inc. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University.
Marian Nakada has almost 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson in 1999.
She transitioned to Janssen Business Development where she executed deals to support the expansion of the Biologics portfolio. She joined JJDC, Johnson & Johnson’s corporate venture group, in 2013 and some of her investments include Padlock Therapeutics, CoStim Pharmaceuticals, and Vedanta Biosciences. She is passionate about leveraging Johnson & Johnson’s capabilities to help her portfolio companies succeed. Marian has a B.A. in Biology from Harvard College and a Ph.D. in Pharmacology from the University of Pennsylvania. She is currently on the Boards of Navitor Pharmaceuticals, Twenty-eight Seven Therapeutics, Ribon Therapeutics, Artizan Biosciences as well as the New England Venture Capital Association where she is working to champion change as an active contributor to its Diversity & Inclusion Committee.